Caroline Tosch, et al. Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article Publication
Catégorie : Publication
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
Christelle Remy-Ziller, et al. Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article Publication
A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8 Download the poster here Poster Presentation
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur Human Vaccines and Immunotherapeutics, August 2017 – Read the article Publication
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al. ASCO 2017, June 2017 – Download the abstract Abstract
In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC
Sandrine Cochin, et al. CLARA, Forum de la recherche en cancérologie, April 2017 Download the poster here Poster Presentation
Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
Laetitia Fend, et al. AACR, American Association for cancer Research, April 2017 Download the poster here Poster Presentation
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al. Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article Publication TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al. Journal for ImmunoTherapy of Cancer, January 2017 – Download the article Publication